Navigation Links
Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
Date:4/8/2009

BALTIMORE, April 8 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary, Champions Biotechnology UK Ltd. (CBUK), to expand its personalized oncology business. Guy Malchi has been appointed General Manager of the UK subsidiary, which will also have a branch in Israel.

"We have been experiencing an increase in activity in all of our business, particularly in our personalized oncology service. Significantly, much of the increased activity in our personalized oncology business is from leading oncologists in Europe as they recognize the enhancement to their practice that is available by utilizing Champions' services. Champions Biotechnology UK Ltd. will enable our services to be accessible to many more physicians in Europe and beyond. The growing trend of medical tourism in Israel has prompted us to establish a branch in Israel to offer our services there as well," said Doug Burkett, PhD, President of Champions Biotechnology, Inc.

Dr. Burkett continued, "I am delighted to welcome Guy Malchi on board as he transitions from consultant to take on the leadership role for CBUK. He will also lead our corporate development efforts, which are focused on in-licensing and co-development of oncology drug candidates that have proven successful in our Biomerk Tumorgraft(TM) platform. Guy's expertise in strategy implementation and business development are a valuable benefit to Champions."

"I am thrilled to join Champions Biotechnology to help it realize its high potential," said Mr. Malchi. "I was drawn to the unique interaction between personalized medicine and drug development, and I look forward to contributing to the firm's success."

Guy Malchi, MBA brings more than twelve years
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
9. Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million
10. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
11. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... San Bruno, CA. (PRWEB) March 04, 2015 ... Organization (CRO) headquartered in the San Francisco Bay Area, ... Clinical Trials (OCT) Israel Conference 2015 on March ... PRC Clinical seeks to build relationships with Israeli life ... Administration (FDA) clinical trials. The company’s services span all ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/4/2015)...   ... Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte Kette ... (NYSE: PHG, AEX: PHIA) gab heute seine ... bekannt, der vom 4. bis 8. März in ... Nr. 102 and 110 wird das Unternehmen ...
Breaking Biology Technology:USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... ... 16 Reportlinker.com announces that a new ... , The Future of Nutrigenomics: New ... , http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores ...
... , -- Company to Host Clinical Update Conference Call ... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today announced that ... Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its ... carboplatin in patients with platinum-refractory head and neck cancers. This ...
... , , , , ROCKVILLE, Md. ... VNDA ), a biopharmaceutical company focused on the development and ... financial and operational results for the fourth quarter and full year ... net loss of $9.2 million for the fourth quarter ...
Cached Biology Technology:Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 11Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 12Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 13Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 14Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 15Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 16Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 17Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 18
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... people may joke about living on caffeine, but scientists ... to do that literally. Their report in the ... "addicted" to caffeine in a way that promises practical ... medications for asthma. Jeffrey E. Barrick and colleagues ...
... March 26, 2013 Like it or not and despite ... du jour for movie-making in Hollywood. It now turns out ... According to a new study published in Biological ... distinct systems: one system that directs attention to affective states ...
... treating Lyme disease. However, nearly one quarter of ... available serological tests have poor sensitivity and specificity ... may go untreated and thus progress to late-stage ... invasive treatments, as well as persistent symptoms. ...
Cached Biology News:Human emotion: We report our feelings in 3-D 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4
... which pioneered the blending of thermostable DNA ... Expand Long Template PCR Systems, now introduces ... the first product of a family of ... combines Taq DNA Polymerase with a novel ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
... 3'CGGN NNNNCCG5' Inactivation Conditions: Heat inactivation at ... followed by ethanol precipitation. Storage Conditions: 10mM ... 1.0mM DTT, 0.01% BSA, 50% glycerol. Shipping ... at -20C. Unit Definition: One unit is ...
...
Biology Products: